H.R. 10227
INSULIN Act of 2026
Summary:
• The INSULIN Act of 2026 caps insulin cost-sharing at $35 per 30-day supply (or 25% of the negotiated net price, whichever is less) for insured individuals, with no deductibles allowed, effective for plan years beginning January 1, 2028.
• The bill establishes a federally funded resource center and 24/7 hotline to help uninsured individuals access affordable insulin assistance programs, authorized at $2 million per year from 2027–2032.
• The bill creates an expedited review pathway for biosimilar insulin products when fewer than 3 biosimilars exist for a given reference product and all exclusivity periods have expired for at least 3 years.
---
• The bill establishes a federally funded resource center and 24/7 hotline to help uninsured individuals access affordable insulin assistance programs, authorized at $2 million per year from 2027–2032.
• The bill creates an expedited review pathway for biosimilar insulin products when fewer than 3 biosimilars exist for a given reference product and all exclusivity periods have expired for at least 3 years.
---